Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
View in:
PubMed
subject areas
Adult
Aged
Angiogenesis Inhibitors
Female
Glucose
Humans
Indoles
Lymphocytes
Magnetic Resonance Imaging
Male
Melanoma
Middle Aged
Neoplasm Metastasis
Neovascularization, Pathologic
Protein Kinase Inhibitors
Pyrroles
Time Factors
Treatment Outcome
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
authors with profiles
Milica Medved
Walter M. Stadler
Gregory Karczmar
Thomas F. Gajewski